金刚烷胺对创伤性脑损伤患者疗效的荟萃分析
结果显示金刚烷胺组认知功能显著优于对照组(MD 0.50,95%CI 0.33-0.66,P<0.001,低确定性证据)。亚组分析提示伤后第一周内开始用药、疗程<1个月、年龄<18岁或较轻TBI患者效应更明显。不良事件无显著差异(OR 1.74,95%CI 0.88-3.44,P=0.11,中等确定性)。结论认为金刚烷胺可能改善认知功能,但需更高质量研究证实。
要点
- 金刚烷胺可能改善TBI后认知功能(MD 0.50,95%CI 0.33-0.66,P<0.001,16项研究,1127例,低确定性证据)。
- 伤后第一周内开始金刚烷胺对认知改善有显著效应(MD 0.97,95%CI 0.45-1.49,低确定性)。
- 金刚烷胺疗程<1个月时效应更明显(MD 0.83,95%CI 0.56-1.11,低确定性)。
- 年龄<18岁患者(MD 0.66,95%CI 0.32-0.99)或较轻TBI患者(MD 0.40,95%CI 0.18-0.62)效应更明显(低确定性)。
- 金刚烷胺与对照组不良事件无统计学差异(OR 1.74,95%CI 0.88-3.44,P=0.11,中等确定性)。
适用人群与场景
- 创伤性脑损伤患者,包括成人及年龄<18岁患者,严重程度涵盖较轻至较重TBI;排除人群原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及金刚烷胺的具体剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 主要终点:金刚烷胺组认知功能显著优于对照组(MD 0.50,95%CI 0.33-0.66,P<0.001,16项研究,1127例,低确定性证据)。
- 亚组:队列研究MD 0.79(95%CI 0.34-1.24,极低确定性),RCTs MD 0.40(95%CI 0.25-0.56,中等确定性)。
- 伤后第一周内开始用药MD 0.97(95%CI 0.45-1.49,低确定性);疗程<1个月MD 0.83(95%CI 0.56-1.11,低确定性);年龄<18岁MD 0.66(95%CI 0.32-0.99,低确定性);较轻TBI MD 0.40(95%CI 0.18-0.62,低确定性)。
- 不良事件:金刚烷胺与对照组无统计学差异(OR 1.74,95%CI 0.88-3.44,P=0.11,中等确定性)。
- Meta回归:开始治疗时间与效应量呈统计学显著关系;年龄和TBI严重程度与效应量呈边缘统计学意义。
证据类型、等级与局限
- 证据类型:系统评价/荟萃分析,证据等级Level III;总体证据确定性低,部分亚组为极低至中等确定性。
- 局限:纳入研究异质性大(临床试验与观察性研究混合),总体证据确定性低,需进一步高质量研究证实。
对床旁实践的改变
- 对于TBI后认知功能障碍患者,金刚烷胺可能改善认知功能,可考虑使用(尤其伤后第一周内开始、疗程<1个月、年龄<18岁或较轻TBI患者),但证据确定性低,需个体化决策。
- 不适用人群:原文未明确排除人群;常见陷阱:原文未提及剂量方案,不能将研究方案剂量外推为通用推荐。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury is a global burden. We aimed to perform a meta-analysis to determine the efficacy of amantadine for cognitive performance after traumatic brain injury.
METHODS: The systematic review was prospectively registered on the International Prospective Register of Systematic Reviews website under the registration number CRD42017080044. We used Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines to report the steps of meta-analysis. The search included electronic databases (PubMed, PsycINFO, Embase, Cochrane Library databases, CENTRAL, ProQuest and ClinicalTrials.gov trial registry). Critical care medicine journals and clinical neurology specialty were searched using www.scimagojr.com. There was no publication date restriction. Two authors assessed studies' relevance and extracted data. Studies were assessed for quality using the Cochrane risk of bias tool. Data were analyzed using Comprehensive Meta-analysis Program versions 2.0 and 3.0.
RESULTS: Twenty-six studies out of 3,440 records were included in the systematic review, of which only 14 clinical trials and 6 observational studies were included in the meta-analysis. Amantadine significantly enhanced the cognitive function relative to control group (mean difference [MD], 0.50; 95% confidence interval [CI], 0.33-0.66; p < 0.001, 16 studies, 1,127 participants, low certainty evidence). Consistent significant difference in favor of amantadine relative to control group was found (MD of 0.79 [95% CI, 0.34-1.24], very low certainty evidence, for cohort studies vs. MD of 0.40 [95% CI, 0.25-0.56], moderate certainty evidence, for RCTS). Starting amantadine in the first week after TBI had a significant effect on improving cognitive function (MD, 0.97; 95% CI, 0.45-1.49; 16 studies, 1,127 participants, low certainty). Amantadine showed a better effect when administered for less than 1 month (MD, 0.83; 95% CI, 0.56-1.11; low certainty) and to patients below 18 years of age (MD, 0.66; 95% CI, 0.32-0.99; low certainty) or to patients with less severe traumatic brain injury (MD, 0.40; 95% CI, 0.18-0.62; low certainty). No statistically significant difference existed between amantadine and the control concerning the adverse events (OR, 1.74; 95% CI, 0.88-3.44; p = 0.11, moderate certainty). Metaregression of the different clinical parameters, which are onset of treatment, age, and severity of traumatic brain injury, showed a statistically significant relation between onset of treatment and the effect size of amantadine. The relation between the other two parameters and the effect size of amantadine showed a marginal statistical significance.
CONCLUSION: Amantadine may improve the cognitive function when used after TBI. Further research with high validity is needed to reach a solid conclusion about the use of amantadine in traumatic brain injury.
LEVEL OF EVIDENCE: Systematic review/meta-analysis, level III.
参考来源
- Mohamed MS, El Sayed I, Zaki A, et al. Assessment of the effect of amantadine in patients with traumatic brain injury: A meta-analysis. J Trauma Acute Care Surg. 2022. PMID: 34284464. doi:10.1097/TA.0000000000003363
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。